Grants

Washington State Community Economic Revitalization Board (CERB)

This funding program provides loans and grants to rural communities for public infrastructure to enable future business development. Jurisdictions in rural counties and rural communities may apply for the Prospective Development program if an economic feasibility study demonstrates that private business development is likely to occur as a result of the public improvements. Additional requirements include: Evidence from an economic feasibility study that the project will lead to the creation of a significant number of permanent jobs or generate significant private capital investment; and Applicants must also demonstrate the need for CERB assistance and that no other timely source of funds is available at a reasonably similar rate to the current CERB rate.

Washington State Community Economic Revitalization Board (CERB)

This funding program provides loans and grants to rural communities for public infrastructure to enable future business development. Jurisdictions in rural counties and rural communities may apply for the Prospective Development program if an economic feasibility study demonstrates that private business development is likely to occur as a result of the public improvements. Additional requirements include: Evidence from an economic feasibility study that the project will lead to the creation of a significant number of permanent jobs or generate significant private capital investment; and Applicants must also demonstrate the need for CERB assistance and that no other timely source of funds is available at a reasonably similar rate to the current CERB rate.

NIA - National Institute on Aging

ABSTRACT The overall goal of this work is to refine a novel magnetic resonance imaging (MRI) protocol to assess a cerebrovascular resistance index (CVRi), to apply this protocol in patients with Alzheimer’s disease (AD) to test fundamental hypotheses regarding how CVRi is altered in the setting of elevated amyloid-beta () plaque retention, and to assess how CVRi adjusts following pharmacological reduction of cerebral . Findings are intended to serve as a necessary prerequisite for a larger, longitudinal study that will assess how CVRi may help to triage patients for emerging anti-amyloid therapies based on personalized signatures of parenchymal health. More specifically, accumulation of cerebral  in the arterial vessel walls of patients with AD can reduce vasoreactivity and increase cerebrovascular resistance, and this effect can be assessed using the CVRi defined as the ratio of the mean arterial blood pressure (MAP; mmHg) and cerebral blood flow (CBF; ml blood/100g tissue/min). CVRi has been reported to be directly related to  accumulation in the setting of AD and partly reflects vasotoxicity, vasoconstriction, and decreased response to changes in blood pressure. Furthermore, heterogeneous distribution of  can result in variable vascular resistance and capillary blood transit time heterogeneity, which our lab has shown in other populations to alter oxygen extraction at the tissue level. I have shown that it is possible to non-invasively measure altered capillary transit times by modeling arterial, tissue, and venous blood arrival on non-invasive arterial spin labeling MRI. This method has primarily been applied in patients with cerebrovascular diseases, however, in preliminary data provided here I provide evidence that vascular transit dynamics are also altered in the setting of  accumulation, elevated vascular resistance, and neurodegeneration. This issue is fundamental, as recently approved anti-amyloid therapies alter vascular dynamics and can lead to extravasation events, such as cerebral microbleeds. As such, it is becoming even more relevant to develop an understanding of how  alters vascular health and whether measures of vascular health have relevance for portending cerebral microbleeds, which occur in a significant group of treated patients. Here, I propose to refine methods for assessing the CVRi non-invasively in vivo with MRI, and to pair this assessment with our established measures of vascular transit to better characterize these relationships in patients with AD before and after pharmacological manipulation of cerebral  The study will also be overseen by mentors with complementary expertise in imaging science, cognitive neurology, amyloid angiopathy, neuroradiology, and statistics with an ongoing collaboration, and will leverage recruitment and resources available from an ongoing longitudinal neuroimaging study of anti-amyloid treatments.

NIA - National Institute on Aging

The menopause transition is a key period of increased cardiovascular disease (CVD) risk in women, related in part to changes in vascular health.1 Vascular mechanisms underlying CVD risk during the menopause transition may also influence women’s disproportionate risk of later-life vascular dementia2,3 and Alzheimer’s disease and related dementia (ADRD), which impacts 3x more women than men.4 Vascular health in midlife and thus, the menopause transition, is highly predictive of later-life brain health and dementia risk.5-10 It is currently unknown how vascular mechanisms of brain health change across the stages of the menopause transition.11,12 This critical gap in knowledge limits mechanism-targeted preventive interventions in midlife to reduce the burden of ADRD1,13,14 in aging women. Although cerebral blood flow is a classic and important mechanism of ADRD, our team’s promising preliminary data suggest cerebral pulsatility may be a novel candidate mechanism by which the menopause transition accelerates brain aging and ADRD risk in women. Cerebral pulsatility describes the discontinuous nature of blood flow in the fragile cerebrovasculature that is a key mechanism of cerebrovascular disease.15 Higher cerebral pulsatility16,17 may damage vascular and structural components of the brain over time16-23 and compromise brain health.18-25 Our promising preliminary data shows women i) experience linear reductions in cerebral blood flow, but a disproportionate, non-linear increase in cerebral pulsatility between 45-55 yrs of age (typical age of the menopause transition),26 and ii) are more vulnerable to cerebral pulsatility than men.27 Exaggerated increases in cerebral pulsatility across the menopause transition may contribute to accelerated brain aging in women. This idea is supported by our work identifying vascular contributors to pulsatility (large artery stiffness and characteristic impedance) that are altered in women during midlife28 and the menopause transition.29,30 Our recent meta-analysis31 indicates cerebral pulsatility is poorly characterized across the stages of the menopause transition and identified key study design components to directly address this knowledge gap. Our team is uniquely positioned to study cerebral pulsatility across stages of the menopause transition as a plausible vascular mechanism of brain aging and ADRD risk in women,11,12,31 thereby informing future intervention development. These topics align with the scientific areas of interest in sex-specific aging trajectories and mechanisms of ADRD (NOT-AG-21-050/-21-039, NOT-OD-24-079) and key foci of the White House Initiative on Women’s Health Research.

NIA - National Institute on Aging

cSVD-IAC: Project Summary The overarching goal of cSVD- IAC is to characterize the burden of cerebral small vessel disease (SVD) [white matter hyperintensities (WMH), lacunar infarcts, enlarged perivascular spaces, microbleeds, cerebral atrophy, and total cSVD score] as defined by brain MRI in a population-based indigenous African cohort. We will test the relationship between MRI cSVD metrics and retinal imaging cSVD metrics (by fundal photography and optical coherence tomography-angiography) to determine thresholds for predicting and detecting cSVD with a more accessible and affordable approach in low - and middle - income countries and among underserved populations in the US. This will unravel the potential of retinal imaging for prediction and diagnosis of cSVD and cognitive impairment and dementia. Furthermore, we will unmask the modifiable, sex, genetic and blood-based biomarker determinants of cSVD and cognitive phenotypes in the cohort. To achieve this overall goal, we will recruit and characterize an additional 2000 participants to expand an existing cohort of > 1000 older Nigerians (50 yrs+) participating in the population-based Vascular heALth, fraiLty and cognItion in Ageing Nigerians sTudy [VALIANT]. We will undertake brain and retinal imaging and evaluate novel proteomic markers and assess transferability of genetic variants of cSVD among 1200 participants nested within the enlarged cohort (3000) and bank biological samples for future multi-omics and comparative studies with US and other global population-based aging cohorts. We will pursue these aims while training at least 5 African early career researchers (ECRs) and expanding stakeholder engagement. This project will consolidate and expand the growing African AD/ADRD research infrastructure by specifically characterizing cSVD in an under-represented African population. The novel data generated by this study will accelerate deeper understanding of cSVD biology in relation to cognitive impairment and dementia, identify lifestyles, and drug targets for prevention, disease modification and treatment, and ultimately enable the design of effective personalized strategies that will be of benefit to African, US and global populations in keeping with the priorities of the US National Dementia Plan and the recommendation of the National Academy of Medicine. We will accomplish this goal through an excellent partnership between experienced and leading US and African investigators.

Cerritos College Foundation

Cerritos College Foundation is an active grantmaking foundation based in Norwalk, CA. Focus: education. Contact the foundation directly for current funding opportunities.

Young Urban Christians & Artists, Inc.

Local

City of Norwich

Certified Local Government

Town of Roxbury

Certified Local Government

New Milford

Certified Local Government

Town of Enfield

Certified Local Government

Town of Madison

Certified Local Government

Town of East Hartford

Certified Local Government

City of Hartford

Certified Local Government

Westport

Certified Local Government

Town of Westport

Certified Local Government

Town of Fairfield

Certified Local Government

Town of Wethersfield

Certified Local Government

Town of Tolland

Certified Local Government

Town of Woodbury

Certified Local Government

Town of Hebron

Certified Local Government

Town of Vernon

Certified Local Government

Salisbury

Certified Local Government

Town of Ledyard

Certified Local Government